Reuters
Individual Analyses of Bias in Reuters Articles
In addition to conducting full-scale reviews of media outlets for overall bias — using methodologies such as Blind Bias Surveys and Editorial Reviews — AllSides sometimes evaluates the bias of an individual news article for bias.
The AllSides editorial team has detected common types of media bias in some individual Reuters articles, including word choice bias, bias by placement, slant, and spin. Read our analysis of each story on the AllSides Perspectives blog:
Type of Content
Approved Story
1
Format
Region
News Item Format
Standard
Drug makers including BioNTech and Moderna are scrambling to test their COVID-19 vaccines against the new fast-spreading variant of the virus that is raging in Britain, the latest challenge in the breakneck race to curb the pandemic.
Ugur Sahin, chief executive of Germany’s BioNTech, which with partner Pfizer took less than a year to get a vaccine approved, said on Tuesday he needs another two weeks to know if his shot can stop the mutant variant of the virus.
Moderna expects immunity from its vaccine to protect against the variant and is performing more tests in coming weeks to confirm, the company said in a statement to CNN. Moderna did not immediately respond to Reuters’ requests for comment.
The mutation known as the B.1.1.7 lineage may be up to 70% more infectious and more of a concern for children. It has sown chaos in Britain, prompting a wave of travel bans that are disrupting trade with Europe and threatening to further isolate the island country.
Sahin said there are nine mutations on the virus.
While he does not believe any are significant enough to skirt the protection afforded by BioNTech’s mRNA vaccine, which was approved by the European Union on Monday, he said another 14 days or so of study and data collection are needed before offering a definitive answer.